Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
Earnings Data
Report Date
May 19, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.42Last Year’s EPS
-1.35Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 25, 2025
|% Change Since: 13.06%
|Next Earnings Date:May 19, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic partnerships and advancements in drug development programs, notably the successful Series A financing for Neurosterix and progress in the GABAB PAM program. However, challenges remain with decreased income and cash limitations for unpartnered programs, indicating a balanced outlook.Company Guidance
During the 2024 Full Year Financial Results Conference Call, Addex Therapeutics provided comprehensive guidance and updates on various programs and financial metrics. The company highlighted the launch of Neurosterix with a US$65 million Series A financing, alongside securing CHF5 million in cash and a 20% equity stake in Neurosterix. Addex reported making significant progress on its GABAB PAM program, with partner Indivior selecting a drug candidate for substance use disorders and initiating R&D studies. The company is eligible for up to US$330 million in milestone payments and tiered royalties. Addex also emphasized the advancement of its independent GABAB PAM program for chronic cough, aiming to start IND-enabling studies this year. Financially, the company ended 2024 with CHF3.3 million in cash, expecting it to sustain operations until mid-2026. The Neurosterix transaction was noted to have reduced cash burn and secured CHF5 million for Addex, with strategic emphasis on leveraging its 20% interest in Neurosterix for future clinical advancements.Successful Series A Financing
In 2024, the company launched Neurosterix with a US$65 million Series A financing led by Perceptive Advisors, securing financing for the platform and pre-clinical portfolio.
Partnership with Indivior
Partner Indivior selected a compound for development in substance use disorders, with Addex eligible for up to US$330 million in milestone payments and tiered royalties.
Progress in GABAB PAM Program
Completion of the R&D phase delivered multiple drug candidates. IND-enabling studies have started for substance use disorders.
Neurosterix Spin-out
Secured CHF5 million in cash and a 20% equity interest in Neurosterix, removing financing overhang.
Development of Dipraglurant
Repositioning dipraglurant for brain injury recovery with potential for enhancing rehabilitation impact.
---
ADXN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADXN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 25, 2025 | $7.58 | $8.16 | +7.65% |
| Nov 22, 2024 | $8.11 | $7.53 | -7.15% |
| Sep 30, 2024 | $9.05 | $9.77 | +7.96% |
| Jun 06, 2024 | $8.99 | $9.20 | +2.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Addex Therapeutics (ADXN) report earnings?
Addex Therapeutics (ADXN) is schdueled to report earning on May 19, 2025, TBA Not Confirmed.
What is Addex Therapeutics (ADXN) earnings time?
Addex Therapeutics (ADXN) earnings time is at May 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADXN EPS forecast?
ADXN EPS forecast for the fiscal quarter 2025 (Q1) is -1.42.
---